AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35968476 — intervention group
Group type: COMPARATOR
Intervention: Active comparator (15 minutes daily reading)
Number of subjects: 0
Study 35968476 — intervention group
Group type: COMPARATOR
Intervention: Placebo comparator (15 minutes daily reading)
Number of subjects: 0
Study 34815458 — intervention group
Group type: EXPERIMENTAL
Intervention: active tDCS
Number of subjects: 58
Study 34815458 — intervention group
Group type: COMPARATOR
Intervention: sham tDCS
Number of subjects: 58
Study 33654007 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular imaging device
Number of subjects: 135
Study 33654007 — intervention group
Group type: EXPERIMENTAL
Intervention: Fist clenching
Number of subjects: 135
Study 33654007 — intervention group
Group type: COMPARATOR
Intervention: Control group (no interventions)
Number of subjects: 135
Study 32818346 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intraocular suspension 9%
Number of subjects: 414
Study 32818346 — intervention group
Group type: COMPARATOR
Intervention: Topical prednisolone acetate 1%
Number of subjects: 414
Study 32818346 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 414
Study 32883328 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC plus Tocilizumab (8mg/kg, infused over 60 minutes)
Number of subjects: 90
Study 32883328 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC plus Tocilizumab (4mg/kg, infused over 60 minutes)
Number of subjects: 90
Study 32883328 — intervention group
Group type: COMPARATOR
Intervention: SOC alone
Number of subjects: 90
Study 35403793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotadutide (50‐300 μg, once‐daily subcutaneous)
Number of subjects: 41
Study 35403793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 35002336 — intervention group
Group type: EXPERIMENTAL
Intervention: FlexDexTM with 3D visual output
Number of subjects: 40
Study 35002336 — intervention group
Group type: COMPARATOR
Intervention: FlexDexTM with 2D visual output
Number of subjects: 40
Study 35842199 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab
Number of subjects: 145
Study 35842199 — intervention group
Group type: COMPARATOR
Intervention: High-Dose Interferon-α2b (HDI)
Number of subjects: 145
Study 33449378 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Family Therapy (FFT) in addition to Treatment-As-Usual (TAU)
Number of subjects: 120
Study 33449378 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Family Therapy (FFT)
Number of subjects: 120
Study 33449378 — intervention group
Group type: COMPARATOR
Intervention: Treatment-As-Usual (TAU)
Number of subjects: 120
Study 32418801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention clusters (targeted clinician education, prediabetes clinician champion, custom electronic health record report)
Number of subjects: 2992
Study 32418801 — intervention group
Group type: COMPARATOR
Intervention: Control clusters (standard care)
Number of subjects: 2992
Study 32418801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention clusters (adjusted for patient demographics and clinical variables)
Number of subjects: 2992
Study 35999066 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal bridge plating (30 patients)
Number of subjects: 60
Study 35999066 — intervention group
Group type: COMPARATOR
Intervention: External fixation (30 patients)
Number of subjects: 60
Study 35999066 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 34436521 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (70 mg/m2 on day 1) and Gemcitabine (1000 mg/m2 on days 1 and 8 of a 21-day cycle)
Number of subjects: 87
Study 34436521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (60 mg/m2 on day 1), Gemcitabine (875 mg/m2 on days 1 and 8), and Berzosertib (90 mg/m2 on days 2 and 9 of a 21-day cycle)
Number of subjects: 87
Study 33189801 — intervention group
Group type: EXPERIMENTAL
Intervention: Recharged NACP adhesive
Number of subjects: 2
Study 33189801 — intervention group
Group type: COMPARATOR
Intervention: Dentin control
Number of subjects: 2
Study 32358417 — intervention group
Group type: EXPERIMENTAL
Intervention: KDB-Phaco
Number of subjects: 164
Study 32358417 — intervention group
Group type: COMPARATOR
Intervention: iStent-Phaco
Number of subjects: 164
Study 32800891 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal treadmill walking test with Gardner's protocol
Number of subjects: 40
Study 32800891 — intervention group
Group type: COMPARATOR
Intervention: Control (standing on treadmill)
Number of subjects: 40
Study 32343190 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (n = 72)
Number of subjects: 136
Study 32343190 — intervention group
Group type: COMPARATOR
Intervention: Wellness education control condition (n = 64)
Number of subjects: 136
Study 34030899 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pack kept in the refrigerator applied to the area above the IV catheter before drug infusion
Number of subjects: 120
Study 34030899 — intervention group
Group type: COMPARATOR
Intervention: Cold pack kept at room temperature applied in the placebo group
Number of subjects: 120
Study 34030899 — intervention group
Group type: COMPARATOR
Intervention: Routine drug infusion without cold application in the control group
Number of subjects: 120
Study 32944806 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-site rTMS (auditory + prefrontal)
Number of subjects: 0
Study 32944806 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory cortex only rTMS (AC)
Number of subjects: 0
Study 32944806 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 32167976 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (20 μg) inhaled
Number of subjects: 40
Study 32167976 — intervention group
Group type: COMPARATOR
Intervention: Saline inhaled (Control)
Number of subjects: 40
Study 34783035 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral stimulation
Number of subjects: 27
Study 34783035 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral stimulation with hands near
Number of subjects: 27
Study 34783035 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall pain rating
Number of subjects: 27
Study 34783035 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral stimulation with hands far
Number of subjects: 27
Study 34510226 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting less regimen (sitting 9 h/day, standing 4 h/day, walking 3 h/day)
Number of subjects: 12
Study 34510226 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise regimen (sitting 13 h/day, exercise 1 h/day)
Number of subjects: 12
Study 34510226 — intervention group
Group type: COMPARATOR
Intervention: Sitting regimen (sitting 14 h/day)
Number of subjects: 12
Study 32051312 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinded n-of-1 trial
Number of subjects: 90
Study 32051312 — intervention group
Group type: COMPARATOR
Intervention: Blinded n-of-1 trial (positive control)
Number of subjects: 90
Study 32051312 — intervention group
Group type: COMPARATOR
Intervention: Usual care (negative control)
Number of subjects: 90
Study 34651190 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole 2.5mg/kg
Number of subjects: 170
Study 34651190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 33871635 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber (DF) supplementation in low crude protein (CP) diet
Number of subjects: 77
Study 33871635 — intervention group
Group type: COMPARATOR
Intervention: Low CP diet
Number of subjects: 77
Study 33871635 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber (DF) supplementation
Number of subjects: 77
Study 33035370 — intervention group
Group type: EXPERIMENTAL
Intervention: Agility Boot Camp with Cognitive Challenge (ABC-C) exercise program
Number of subjects: 82
Study 32870957 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced Auditory Serial Addition Task (PASAT)
Number of subjects: 15
Study 32870957 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 15
Study 34411333 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) treatment
Number of subjects: 27
Study 32913154 — intervention group
Group type: COMPARATOR
Intervention: Intra-rectal xylocaine gel (10 mls)
Number of subjects: 2
Study 32913154 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical peri-prostatic nerve block (10 mls of 1% xylocaine)
Number of subjects: 2
Study 32913154 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2
Study 35247264 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 2014
Study 35247264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2014
Study 32124566 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 0.3 g/kg SB
Number of subjects: 288
Study 32124566 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 0.6 g/kg SB
Number of subjects: 288
Study 32124566 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 1.2 g/kg SB
Number of subjects: 288
Study 32124566 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary SB supplementation
Number of subjects: 288
Study 32124566 — intervention group
Group type: COMPARATOR
Intervention: CON, basal diet
Number of subjects: 288
Study 35927706 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% tetra sodium pyrophosphate
Number of subjects: 64
Study 35927706 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride
Number of subjects: 64
Study 32875722 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially guided surgery (PGS, n = 12)
Number of subjects: 24
Study 32875722 — intervention group
Group type: COMPARATOR
Intervention: Fully guided surgery (FGS, n = 12)
Number of subjects: 24
Study 34404477 — intervention group
Group type: EXPERIMENTAL
Intervention: NMT
Number of subjects: 46
Study 34404477 — intervention group
Group type: EXPERIMENTAL
Intervention: NMT plus EF
Number of subjects: 46
Study 33026127 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA)
Number of subjects: 32
Study 33026127 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC)
Number of subjects: 32
Study 33026127 — intervention group
Group type: COMPARATOR
Intervention: Serum cortisol
Number of subjects: 32
Study 34475868 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned treatment interruption
Number of subjects: 8
Study 34475868 — intervention group
Group type: COMPARATOR
Intervention: Continuous treatment
Number of subjects: 8
Study 33891472 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1,200 mg plus platinum-based chemotherapy (paclitaxel plus carboplatin) and bevacizumab 15 mg/kg
Number of subjects: 1301
Study 33891472 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus platinum-based chemotherapy (paclitaxel plus carboplatin) and bevacizumab 15 mg/kg
Number of subjects: 1301
Study 33891472 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 1301
Study 33891472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1301
Study 33891472 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab and placebo
Number of subjects: 1301
Study 35768286 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) plus levocabastine nasal spray
Number of subjects: 40
Study 35768286 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate nasal spray (MFNS) plus placebo nasal spray
Number of subjects: 40
Study 34446497 — intervention group
Group type: EXPERIMENTAL
Intervention: CytoSorb therapy (continuous for at least 24 hours, adsorber device changed every 12 hours)
Number of subjects: 135
Study 34446497 — intervention group
Group type: EXPERIMENTAL
Intervention: CytoSorb therapy (continuous for at least 24 hours, adsorber device changed every 24 hours)
Number of subjects: 135
Study 34446497 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 135
Study 32386466 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based multimodal physical therapy
Number of subjects: 62
Study 32386466 — intervention group
Group type: COMPARATOR
Intervention: Primary-care physical therapy
Number of subjects: 62
Study 37528476 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of Er:YAG and long-pulsed Nd:YAG lasers
Number of subjects: 24
Study 37528476 — intervention group
Group type: COMPARATOR
Intervention: Er:YAG laser therapy only
Number of subjects: 24
Study 33017844 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting (IF) for 8 weeks
Number of subjects: 39
Study 33017844 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting (IF)
Number of subjects: 39
Study 33017844 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 39
Study 35141517 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ethyl chloride spray (ECS)
Number of subjects: 110
Study 35141517 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous 1% lidocaine injection (LI)
Number of subjects: 110
Study 32305094 — intervention group
Group type: EXPERIMENTAL
Intervention: LLINs with piperonyl butoxide (PBO)
Number of subjects: 5200
Study 34551650 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric root extract supplementation
Number of subjects: 12
Study 34551650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 35145610 — intervention group
Group type: EXPERIMENTAL
Intervention: Bathysmed® protocol (meditative scuba diving)
Number of subjects: 0
Study 35145610 — intervention group
Group type: COMPARATOR
Intervention: Multisport program (control)
Number of subjects: 0
Study 33600197 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI + BA
Number of subjects: 113
Study 33600197 — intervention group
Group type: COMPARATOR
Intervention: BMI + SC
Number of subjects: 113
Study 33180863 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention group (n = 143)
Number of subjects: 299
Study 33180863 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 156)
Number of subjects: 299
Study 36180836 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning based on electronic health record (EHR) data directing supplemental clinical evaluations
Number of subjects: 0
Study 36180836 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical workflow
Number of subjects: 0
Study 34092234 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised nutrition advice (L1, L2, L3)
Number of subjects: 1270
Study 34092234 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised nutrition advice (L3)
Number of subjects: 1270
Study 34092234 — intervention group
Group type: COMPARATOR
Intervention: Generalised dietary advice (control)
Number of subjects: 1270
Study 32216150 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)
Number of subjects: 23
Study 32216150 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 23
Study 35839214 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Number of subjects: 54
Study 35839214 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation and resistance training
Number of subjects: 54
Study 35839214 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 35839214 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing physical activity (PA)
Number of subjects: 54
Study 34874142 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite toothpaste
Number of subjects: 21
Study 34874142 — intervention group
Group type: COMPARATOR
Intervention: Amine fluoride toothpaste
Number of subjects: 21
Study 35636621 — intervention group
Group type: EXPERIMENTAL
Intervention: Decipher genomic classifier low–intermediate
Number of subjects: 350
Study 32134342 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) with intra-operative CT scanning
Number of subjects: 0
Study 36094783 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarter-dose combination of amlodipine, telmisartan, and chlorthalidone
Number of subjects: 176
Study 36094783 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose combination of amlodipine, telmisartan, and chlorthalidone
Number of subjects: 176
Study 36094783 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-dose combination of amlodipine, telmisartan, and chlorthalidone
Number of subjects: 176
Study 36094783 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 176
Study 36094783 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 176
Study 36094783 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 176
Study 36094783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 33155348 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally Adapted Cognitive Behavioral Therapy Plus Problem Management (CA-CBT+)
Number of subjects: 24
Study 33155348 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (WLC)
Number of subjects: 24
Study 36920567 — intervention group
Group type: EXPERIMENTAL
Intervention: taVNS (transcutaneous auricular vagus nerve stimulation)
Number of subjects: 22
Study 36920567 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (earlobe stimulation)
Number of subjects: 22
Study 34400673 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization with GLY1 and SKP1
Number of subjects: 0
Study 34400673 — intervention group
Group type: COMPARATOR
Intervention: Traditional RGs (eIF1α and ACT2)
Number of subjects: 0
Study 35794487 — intervention group
Group type: EXPERIMENTAL
Intervention: Peloid therapy and home exercise
Number of subjects: 80
Study 35794487 — intervention group
Group type: COMPARATOR
Intervention: Paraffin therapy and home exercise
Number of subjects: 80
Study 34582572 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 5601
Study 34582572 — intervention group
Group type: COMPARATOR
Intervention: Regional anaesthesia
Number of subjects: 5601
Study 33355078 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid administration at the beginning of RARP
Number of subjects: 100
Study 33355078 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tranexamic acid)
Number of subjects: 100
Study 34775453 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable collamer lens (ICL) V4c
Number of subjects: 50
Study 34775453 — intervention group
Group type: COMPARATOR
Intervention: Refractive implantable lens (RIL)
Number of subjects: 50
Study 34775453 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ICL and RIL
Number of subjects: 50
Study 32741375 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated contoured foot orthoses
Number of subjects: 40
Study 32741375 — intervention group
Group type: COMPARATOR
Intervention: Flat shoe insoles
Number of subjects: 40
Study 33686160 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadherent group (n=59)
Number of subjects: 92
Study 33686160 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherent group (n=33)
Number of subjects: 92
Study 33686160 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence measured by MEMS
Number of subjects: 92
Study 32040244 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-E
Number of subjects: 143
Study 32040244 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 143
Study 36493504 — intervention group
Group type: EXPERIMENTAL
Intervention: Punitive parenting behaviors during drinking events
Number of subjects: 0
Study 36493504 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive parenting behaviors the morning after drinking
Number of subjects: 0
Study 34100149 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) 800/150/200/10 mg
Number of subjects: 1106
Study 35631257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric sodium EDTA in combination with vitamin C, folic acid, copper gluconate, zinc gluconate, and selenomethionine (Group 2; N = 22)
Number of subjects: 62
Study 35631257 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous sulfate (Group 1; N = 20)
Number of subjects: 62
Study 35631257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric liposomal formulation (Group 3; N = 20)
Number of subjects: 62
Study 34186278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided retrolaminar block (RLB)
Number of subjects: 65
Study 34186278 — intervention group
Group type: COMPARATOR
Intervention: Ilioinguinal nerve block (INB)
Number of subjects: 65
Study 35630079 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored 12-week remote physiotherapy program
Number of subjects: 21
Study 35630079 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued target medical therapy only)
Number of subjects: 21
Study 34611847 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) - 20 sessions on the right supplementary motor area
Number of subjects: 12
Study 32004757 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 0
Study 32089822 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-NP+M1 co-administered with licensed inactivated quadrivalent influenza vaccine
Number of subjects: 2030
Study 32089822 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 2030
Study 35042370 — intervention group
Group type: EXPERIMENTAL
Intervention: NAMI Basics (peer-led family support program)
Number of subjects: 111
Study 35042370 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition (control group)
Number of subjects: 111
Study 33580623 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative FOLFOX (four cycles before surgery and eight cycles after)
Number of subjects: 104
Study 33580623 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant FOLFOX (upfront surgery)
Number of subjects: 104
Study 32178765 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg every 4 weeks
Number of subjects: 381
Study 32178765 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg every 8 weeks
Number of subjects: 381
Study 32178765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study 33292022 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSO‐524® (600 mg/d)
Number of subjects: 51